Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Plus Therapeutics Charts.

Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Plus Therapeutics Charts.

Plus Therapeutics Inc News

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
Wednesday 26 February 2025 (20 hours ago) • GlobeNewswire Inc.

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
Monday 24 February 2025 (3 days ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 20 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 20 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 20 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 20 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 20 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 20 February 2025 (6 days ago) • Edgar (US Regulatory)

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
Thursday 20 February 2025 (7 days ago) • GlobeNewswire Inc.

Form 424B3 - Prospectus [Rule 424(b)(3)]
Tuesday 18 February 2025 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 18 February 2025 (1 week ago) • Edgar (US Regulatory)

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
Tuesday 18 February 2025 (1 week ago) • GlobeNewswire Inc.

More Plus Therapeutics Inc News Articles

TransCode Therapeutics

MineralRite (PK)

CyberFuels (PK)

Valiant Eagle (PK)

Good Vibrations Shoes (PK)

Voip Pal Com (QB)

TPT Global Tech (PK)

Digital Brand Media and ... (PK)

RespireRx Pharmaceuticals (CE)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions